MarginsXMarginsX
Home › Markets › Health Care › JSPR

Jasper Therapeutics Inc. (JSPR)

JSPR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$11.77
-13.96% on the day
Market cap
$13.1M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerJSPR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001788028
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
1.5 months
$7.3M cash at June 30, 2026
Share count, 1 year
+104.7%
2025-08-11 to 2026-08-10 · +200.3% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern."
10-Q 2026-08-14
Cash and burn$7.3M cash; operating cash flow -$15.1M a quarter.Report 2026-06-30
Shares outstanding1,109,152 (2026-08-10); 16,253,332 a year earlier; 110,800,413 three years earlier. 3y figure adjusted for splits (1-for-10 overall).Cover page 2026-08-10
Reverse splits, 3 years2; latest 1-for-30 on 2026-11-06Source 2026-11-06
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-10-14
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-06-09
Delisting25-NSE filed25-NSE 2026-09-24
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-04-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$2.8M-$6.9M$7.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$1.2M-$14.5M$14.1MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
Not filed-$9.1M-$21.9M$28.7MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$18.7M-$17.0M$50.9MNo debt tagsNeeds four quarters10-Q 2025-11-10
Q2 2025
2025-06-30
Not filed-$26.7M-$15.5M$39.5MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$21.2M-$22.8M$48.8MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q4 2024
2024-12-31
Not filed-$24.3M-$21.1M$71.6MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$18.6M-$14.1M$92.5MNo debt tagsNeeds four quarters10-Q 2025-11-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
S-32026-10-14
Latest annual report
AMENDMENT NO. 1 TO FORM 10-K
10-K/A2026-04-30
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-16
Latest current report
CURRENT REPORT
8-K2026-11-16
Latest proxy
PROXY STATEMENT
DEF 14A2026-10-19

Source: SEC EDGAR submissions feed, 489 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-18.9%
1 month-8.1%
3 months-47.2%
Year to date-75.1%
1 year-71.7%
From 52-week high-77.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
DYAIDyadic International Inc.$0.3200-2.14%$12.8M
PASGPassage Bio Inc.$4.13-2.82%$13.3M
ATYRaTyr Pharma Inc.$5.24-14.17%$13.4M
BCDABioCardia Inc.$0.7901-4.92%$12.0M
PLURPluri Inc.$1.04-0.95%$15.0M
ABOSAcumen Pharmaceuticals Inc.$0.2160+0.93%$15.6M
SCLXScilex Holding Company$1.25-12.59%$10.6M
ALGSAligos Therapeutics Inc.$1.66-20.95%$10.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier